Establishment Labs Announces Participation in The Aesthetic Meeting 2022 and Sessions of Interest

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in The Aesthetic Meeting 2022 from April 20-24 in San Diego, California. Dr. Caroline Glicksman will present an update on the Motiva US Core Clinical Study on April 21 at 3:50pm PT. The company will also host an event honoring Dr. Brian Kinney's contributions to plastic surgery and women's health. Established in 2010, Establishment Labs specializes in breast aesthetics and reconstruction, delivering approximately 2.0 million Motiva Implants in over 80 countries.

Positive

• Participation in The Aesthetic Meeting 2022 enhances visibility.
• Dr. Caroline Glicksman's presentation may attract interest in Motiva Implants.
• Honoring Dr. Brian Kinney underscores the company's commitment to women's health.

Negative

• None.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its participation in The Aesthetic Meeting 2022, which is being held April 20-24 in San Diego, California, as well as sessions of interest at the meeting.

Dr. Caroline Glicksman, the Medical Director for and a Principal Investigator in the Motiva US IDE Study, will present an update on the clinical trial after completion of two-year follow-up on the augmentation cohort. The presentation, Motiva US Core Clinical Study Update, is part of the Aesthetic Surgery Education and Research Foundation (ASERF) Premier Global Hot Topics session and is scheduled for 3:50pm PT on April 21.

Establishment Labs will also host an event the evening of April 21 celebrating Dr. Brian Kinney and his more than 30 years of contributions to plastic surgery, medical and scientific research, and women’s health. Dr. Kinney maintains a private practice in Beverly Hills, California and is a Clinical Associate Professor of Plastic Surgery at the University of Southern California. He has lectured in over 70 countries, authored over 65 peer-reviewed publications, and is a member of the Establishment Labs Scientific Advisory Board.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants^® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, approximately 2.0 million Motiva Implants^® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora^® tissue expander and Motiva MIA^®, the company’s minimally invasive breast enhancement offering. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant^® and began a clinical trial to support regulatory approval in the United States. Motiva Implants^® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the Company’s annual report on Form 10-K filed on March 1, 2022, quarterly reports on Form 10-Q, and other filings made by the Company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005218/en/

Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

What will Establishment Labs present at The Aesthetic Meeting 2022?

Establishment Labs will present an update on the Motiva US Core Clinical Study on April 21, 2022.

When is The Aesthetic Meeting 2022?

The Aesthetic Meeting 2022 will be held from April 20 to April 24 in San Diego, California.

What is the significance of the Motiva US IDE Study?

The Motiva US IDE Study is pivotal for the clinical evaluation of Motiva Implants, which are designed for breast aesthetics.

How many countries has Establishment Labs delivered Motiva Implants to?

Establishment Labs has delivered approximately 2.0 million Motiva Implants to plastic surgeons in over 80 countries.